229 related articles for article (PubMed ID: 17283252)
1. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
2. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
3. Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.
Peng H; Carretero OA; Raij L; Yang F; Kapke A; Rhaleb NE
Hypertension; 2001 Feb; 37(2 Pt 2):794-800. PubMed ID: 11230375
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitors: a new mechanism of action.
Peng H; Carretero OA; Vuljaj N; Liao TD; Motivala A; Peterson EL; Rhaleb NE
Circulation; 2005 Oct; 112(16):2436-45. PubMed ID: 16216963
[TBL] [Abstract][Full Text] [Related]
6. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.
Rhaleb NE; Peng H; Yang XP; Liu YH; Mehta D; Ezan E; Carretero OA
Circulation; 2001 Jun; 103(25):3136-41. PubMed ID: 11425781
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.
Liao TD; Yang XP; D'Ambrosio M; Zhang Y; Rhaleb NE; Carretero OA
Hypertension; 2010 Feb; 55(2):459-67. PubMed ID: 20026760
[TBL] [Abstract][Full Text] [Related]
9. Prevention of aortic fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in angiotensin II-induced hypertension.
Lin CX; Rhaleb NE; Yang XP; Liao TD; D'Ambrosio MA; Carretero OA
Am J Physiol Heart Circ Physiol; 2008 Sep; 295(3):H1253-H1261. PubMed ID: 18641275
[TBL] [Abstract][Full Text] [Related]
10. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans.
Azizi M; Ezan E; Reny JL; Wdzieczak-Bakala J; Gerineau V; Ménard J
Hypertension; 1999 Mar; 33(3):879-86. PubMed ID: 10082503
[TBL] [Abstract][Full Text] [Related]
11. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Liu YH; D'Ambrosio M; Liao TD; Peng H; Rhaleb NE; Sharma U; André S; Gabius HJ; Carretero OA
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H404-12. PubMed ID: 19098114
[TBL] [Abstract][Full Text] [Related]
12. Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I.
Michaud A; Williams TA; Chauvet MT; Corvol P
Mol Pharmacol; 1997 Jun; 51(6):1070-6. PubMed ID: 9187274
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32085655
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects against diabetic kidney disease.
Srivastava SP; Goodwin JE; Kanasaki K; Koya D
Br J Pharmacol; 2020 Aug; 177(16):3691-3711. PubMed ID: 32352559
[TBL] [Abstract][Full Text] [Related]
15. d-amino acid modification protects N-Acetyl-seryl-aspartyl-lysyl-proline from physiological hydroxylation and increases its antifibrotic effects on hepatic fibrosis.
Zhang X; Zhou J; Zhu Y; He L; Pang Z; Wang Z; Xu C; Zhang C; Hao Q; Li W; Zhang W; Zhang Y; Li M
IUBMB Life; 2019 Sep; 71(9):1302-1312. PubMed ID: 30900390
[TBL] [Abstract][Full Text] [Related]
16. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
[TBL] [Abstract][Full Text] [Related]
17. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Preziuso C; Leopizzi M; Maestroni S; Corradi B; Zerbini G; Stella A
Am J Nephrol; 2013; 37(1):65-73. PubMed ID: 23327833
[TBL] [Abstract][Full Text] [Related]
18. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
19. Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats.
Worou ME; Liao TD; D'Ambrosio M; Nakagawa P; Janic B; Peterson EL; Rhaleb NE; Carretero OA
Hypertension; 2015 Oct; 66(4):816-22. PubMed ID: 26324505
[TBL] [Abstract][Full Text] [Related]
20. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]